Physician profile
Francis Yap
NPI 1235234337
$17,078.43
in general payments reported to CMS, 2019-2025
52 companies · $2,845 in 2025
The $2,845 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,473 · 2020: $2,017 · 2021: $2,259 · 2022: $1,924 · 2023: $2,799 · 2024: $2,761 · 2025: $2,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,405.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,405.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,502.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,073.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,705.97 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $1,118.76 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,001.97 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $979.92 | 2019-2025 | |
| Amgen INC. | $910.10 | 2020-2025 | Repatha, Evenity, Repatha |
| Glaxosmithkline, LLC. | $867.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $523.20 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $493.55 | 2022-2025 | |
| Abbvie INC. | $458.88 | 2021-2025 | Ubrelvy |
| Amarin Pharma, INC. | $448.74 | 2019-2021 | |
| Corcept Therapeutics | $395.68 | 2023-2025 | Korlym |
| Merck Sharp & Dohme LLC | $368.04 | 2019-2025 | Capvaxive, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $221.88 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Yap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.